AGC Biologics Capacity Update April 2025: ADC

The Proveo™ alliance is an ADC program wth 15 years of experience offering developers end-to-end support for their ADC project. Proveo leverages AGC Biologics' specialized expertise in monoclonal antibody production, with Cerbios' proficiency in bioconjugation and linker-payload, while Oncotec provides aseptic fill and lyophilization of the ADC drug product — all in one easy-to-manage contract.

This presentation gives a global overview of the program for developers needing the full end-to-end support, without the headache of dealing with multiple contracts.